Brief: Crossject Announces Commercial Agreement With DESITIN Pharma In Germany
18/06/2019 17:00
June 18 (Reuters) - CROSSJECT SA ALCJ.PA :
* COMMERCIAL AGREEMENT WITH DESITIN PHARMA ON ZENEO
MEDIAZOLAM IN
GERMANY
* € 2.5 MILLION TO BE RECEIVED BY CROSSJECT BY THE TIME OF
MARKETING
Source text for Eikon: ID:nGNE2rttVk
Further company coverage: ALCJ.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Crossject SA
See all newsBrief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure